CNSP News and Press, CNS Pharmaceuticals Inc. From 03/07/22

The company also participated in the H.C. Wainwright BioConnect Conference earlier in January CNS Pharmaceuticals recently received approval from swissethics for a pivotal Berubicin and GBM clinical trial The five-year survival rate for GBM is only 6.8%, with the average patient popul...

A new study has found that naked mole rats demonstrate exceptional resistance to cancer and aging. Naked mole rats have long interested researchers involved in cancer research and aging research. Recently, researchers from the Kumamoto University in Japan succeeded in isolating stem cell...

CNS Pharmaceuticals press release (NASDAQ:CNSP): FY Net Loss of $14M As of December 31, 2021, the Company had cash of approximately $5M and working capital of approximately $5.3M. Shares -1.24% PM. For further details see: CNS Pharmaceuticals reports FY results

CNS Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update 2021 marked by operational advancements on clinical and regulatory fronts Company continues to execute progression of lead program, Berubicin, in ongoing potentially pivotal global cli...

A new study has found that an experimental herpes simplex virus may help fight glioblastoma brain tumors . Glioblastoma brain tumors have an average survival period of 12 to 15 months from when one individual receives a  diagnosis and four to six months after they recur. Dr. James Ma...

A new study has found that asthma causes T lymphocyte cells in the body to induce inflammation of the lungs and also prevent the growth of brain tumors. T lymphocyte cells, or T cells, are a type of immune cells that become activated when an individual develops asthma, a breathing diseas...

Researchers at the Catholic University of the Sacred Heart medical school in Italy and Johns Hopkins Medicine in Boston have found new evidence suggesting that a prospective copper therapy can be used to help save children suffering from medulloblastoma. Medulloblastoma is a rapidly grow...

A new study has found that chemotherapy that is administered at night can target brain tumors better, as observed in mouse models, in comparison to day-time administered chemotherapy. The researchers hypothesize that the blood-brain barrier may allow the cancer treatment to pass through mo...

CNS Pharmaceuticals (NASDAQ: CNSP) recently received approval from swissethics, the umbrella organization of the cantonal Ethics Committees in Switzerland. The first from a European Ethics Committee, the approval marks a significant milestone for the company as it journeys toward its poten...

New research has found that the combined use of radiation and IL-7 (interleukin 7), which is an immune-boosting protein, improves survival rates for mice with glioblastoma. Glioblastoma is a cancer that occurs in an individual’s spinal cord or brain. The conventional treatment for...